U.S. Senator Tammy Baldwin to Pfizer CEO: Make Drug Price Reductions Permanent
Major drug companies have drastically raised prices for top-selling drugs over the past five years, in some cases more than doubling prices.
WASHINGTON, D.C. – U.S. Senator Tammy Baldwin today sent a letter to the CEO of Pfizer calling on the pharmaceutical company to make recently announced price reductions permanent. Baldwin’s letter follows an announcement by Pfizer that it would delay announced price hikes after a tweet from President Trump, calling into question why the company needs to increase prices in the first place.
Major drug companies have drastically raised prices for top-selling drugs over the past five years, in some cases more than doubling prices. This is despite increased sales and company profits. Last year, President Trump signed partisan tax legislation passed by Congressional Republicans that gave permanent tax breaks to corporations such as Pfizer. Since then, drug corporations, including Pfizer, have announced more than $50 billion combined in stock buybacks—largely benefiting top executives and wealthy shareholders as prescription drug prices continue to rise for American families. In fact, Pfizer and many other companies instituted price hikes on prescription drugs in January after the corporate tax cut became law. Recently, Pfizer increased prices again and it’s costing consumers.
“Instead of playing games with the costs of prescription drugs that millions of Americans depend on, you should make a firm and clear commitment to permanently roll back prices,” wrote Senator Baldwin in her letter.
Senator Baldwin has been working to hold prescription drug companies accountable for skyrocketing drug prices. Earlier this year, Senators Baldwin and McCain sent a letter to President Trump urging him to hold the pharmaceutical industry accountable and make good on his promise to lower the skyrocketing prescription drug prices that American families are struggling to afford.
Baldwin and McCain also co-authored the bipartisan FAIR Drug Pricing Act, which would begin to address high prescription drug prices and hold pharmaceutical companies accountable by requiring transparency for drug companies that plan to increase drug prices. The bill would not prohibit manufacturers from increasing prices, but it would, for the first time, give taxpayers notice of price increases and bring basic transparency to the market for prescription drugs.
“I have heard from countless Wisconsinites who are struggling to afford medications that they have relied on for years. They want Washington to take real action. That is why I have offered a bipartisan solution, the FAIR Drug Pricing Act, to institute basic transparency and accountability for drug companies that raise prices.” said Senator Baldwin.
The full letter is available here.
Recent Press Releases by U.S. Sen. Tammy Baldwin
"The dangerous levels of PFAS recently detected in Wisconsin surface waters are alarming and warrant serious action."
U.S. Senator Tammy Baldwin Urges Trump Administration to Protect Health Coverage for People with Pre-Existing ConditionsOct 3rd, 2019 by U.S. Sen. Tammy Baldwin
Letter requests HHS and CMS to limit push of “junk” health insurance plans that cover less and cost more
U.S. Senators Tammy Baldwin and Thom Tillis Introduce Bipartisan Legislation to Improve the Quality of Health Care for VeteransSep 27th, 2019 by U.S. Sen. Tammy Baldwin
Bipartisan bill would expand access to training and educational opportunities for future health professionals on veteran-specific health needs